Glioblastoma Multiforme Pipeline Insights 2024 | Clinical Trials, Latest Approvals, Treatment Outlook, Therapies, Companies | Genentech, Merck, Daiichi Sankyo, VBL Therapeutics, Diffusion Pharma

As per DelveInsight's assessment, about 100+ key pharma and biotech companies are working on 100+ pipeline drugs in the Glioblastoma Multiforme therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
The expected launch of potential therapies may increase the Glioblastoma Multiforme market size in the coming years, assisted by an increase in the incident population of Glioblastoma Multiforme. The market is expected to witness a significant positive shift owing to the positive outcomes of several products during the developmental stage by key players such as Bayer, VBL Therapeutics, AstraZeneca, DNAtrix, Kintara Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Immunomic Therapeutics, Treovir, Istari Oncology, Inovio Pharmaceuticals, Northwest Biotherapeutics, and others.

"Glioblastoma Multiforme Pipeline Insight, 2024 [https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Glioblastoma Multiforme Market.

The Glioblastoma Multiforme Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Recent breakthroughs in the Glioblastoma Multiforme Market [https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]:

*
In 2024, Genenta Science (NASDAQ: GNTA) announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to Temferon Trademark for the treatment of glioblastoma multiforme (GBM).

*
In 2024, Jubilant Therapeutics announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to JBI-778 for the treatment of glioblastoma multiforme (GBM). JBI-778 is an oral, brain-penetrant, substrate-competitive protein arginine methyltransferase 5 (PRMT5) inhibitor designed for treating tumors with brain metastases and primary brain tumors, including high-grade glioma.

*
In 2024, Cantex Pharmaceuticals announced that the FDA had granted Orphan Drug Designation to its drug azeliragon, a well-tolerated once-daily pill, for the treatment of glioblastoma.

*
In 2022, Moleculin Biotech, Inc. (NASDAQ: MBRX) announced that the FDA had granted Fast Track designation to WP1122 for the treatment of glioblastoma multiforme.

*
In 2022, Northwest Biotherapeutics (OTCQB: NWBO) reported that their Phase III clinical trial showed increased median survival and extended survival in newly diagnosed and recurrent glioblastoma patients treated with DCVax Registered -L, meeting both primary and secondary endpoints under the trial's Statistical Analysis Plan.

Glioblastoma Multiforme Pipeline Analysis [https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

The report provides insights into:

*
The report provides detailed insights into the emerging therapies for the treatment of Glioblastoma Multiforme and the aggregate therapies developed by major pharma companies.

*
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

*
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Glioblastoma Multiforme market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like -

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Route of Administration

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravitreal

*
Subretinal

*
Topical

Molecule Type

Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Learn How the Ongoing Clinical & Commercial Activities will Affect the Glioblastoma Multiforme Therapeutic Segment @ https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-pipeline-insight [https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Leading Companies in the Glioblastoma Multiforme Therapeutics Market [https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] Include: 3-V Biosciences, ACADIA Pharmaceuticals, Acerta Pharma, Aivita Biomedical, Array Biopharma, Ascletis, AstraZeneca, Autotelic Therapeutics, Bayer, BioMimetix, BioNTech, Bristol Myers Squibb, Celgene Corporation, Chimerix, CNS Pharmaceutical, Cytogel, Denovo Biopharma, DNAtrix, Doule bond Pharmaceuticals, Eisai and Merck Sharp & Dohme, Enterome, Epitopoietic Research Corporation (ERC), Forma Therapeutics, Genenta Science, Immatics N.V, Immunomic Therapeutics, Imvax, Inovio Pharmaceuticals, Istari Oncology, Karyo Pharma, Karyopharm Therapeutics, Kazia Therapeutics, Kintara Therapeutics, Laminar Pharmaceuticals, Mayo Clinic, Medicenna Therapeutics, MedImmune, Merck, MimiVax, Neugate Theranostics, Northwest Therapeutics, Novartis, Noxxon Pharma, Oblato, Oncotelic Therapeutics, Orphelia Pharma, Pfizer, Philogen, Roche, SonALAsense, TME Pharma, VBI Vaccines, Xgene Pharmaceutical, Yumanity Therapeutics, and others

Glioblastoma Multiforme Drugs Profiles:

*
Afatinib: Boehringer Ingelheim

*
AV-GBM-1: Aivita Biomedical

*
Avastin: Genentech

*
AZD1390: AstraZeneca

*
Crenolanib: AROG Pharmaceuticals

*
CYNK 001: Celularity

*
DCVax-L: Northwest Pharmaceuticals

*
Durvalumab (MEDI4736): MedImmune

*
G207: Treovir

*
ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics

*
LAM561 (2-OHOA): Laminar Pharmaceuticals

*
MDNA55: Medicenna Therapeutics

*
Ofranergene obadenovec (VB-111): VBL Therapeutics

*
ONC201: Chimerix

*
Onfekafuspalfa: Philogen

*
Paxalisib (GDC-0084): Kazia Therapeutics

*
PVSRIPO: Istari Oncology

*
Regorafenib: Bayer Healthcare

*
YTX7739: Yumanity Therapeutics

Table of Contents

1. Report Introduction

2. Executive Summary

3. Glioblastoma Multiforme Current Treatment Patterns

4. Glioblastoma Multiforme - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Glioblastoma Multiforme Late Stage Products (Phase-III)

7. Glioblastoma Multiforme Mid-Stage Products (Phase-II)

8. Glioblastoma Multiforme Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Glioblastoma Multiforme Discontinued Products

13. Glioblastoma Multiforme Product Profiles

14. Key Companies in the Glioblastoma Multiforme Market

15. Key Products in the Glioblastoma Multiforme Therapeutics Segment

16. Dormant and Discontinued Products

17. Glioblastoma Multiforme Unmet Needs

18. Glioblastoma Multiforme Future Perspectives

19. Glioblastoma Multiforme Analyst Review

20. Appendix

21. Report Methodology

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glioblastoma-multiforme-pipeline-insights-2024-clinical-trials-latest-approvals-treatment-outlook-therapies-companies-genentech-merck-daiichi-sankyo-vbl-therapeutics-diffusion-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.